The Pharmacy Times® Depression Resource Center is a comprehensive resource for clinical news and expert insights on treatments for the different forms of depression and its symptoms.
November 9th 2023
Pharmacists are accessible and trusted health care professionals who have an important role in supporting people living with mental illness.
October 30th 2023
Therapeutic Strategies for Bipolar Disorder: Recognizing the Intricacies in Disease Management and Considerations for Pharmacists Across Practice Settings
2.0 Credits / Neurology, Psychiatry
View More
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Treatment Advancements and Management Strategies in Bipolar Disorder to Mitigate Challenges to Patient Care
1.0 Credit / Neurology, Psychiatry
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Managing Bipolar Disorder: The Pharmacist’s Role in Delivering Quality Care
1.0 Credits / Psychiatry
View More
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Use of Antidepressants in Older Adults Linked to Driving Impairment on a Road Test
October 9th 2023Use of antidepressants and other classes of prescription drugs can increase the risk of driving impairment compared to nonuse, so clinicians and pharmacists should review these risks with older adults.
Read More
Beyond Depression: Antidepressants and Their Diverse Indications
October 4th 2023An overview of antidepressant medications and their indications to inform health care professionals of their wide use and to better understand which antidepressant to recommend based on patient-specific characteristics.
Read More
FDA Approves Gepirone Extended-Release for Treatment of Major Depressive Disorder
September 28th 2023Gepirone hydrochloride ER (Exxua; Fabre-Kramer Pharmaceuticals Inc) is in a new class of antidepressants, making it the first and only approved antidepressant that selectively targets serotonin 1A receptors.
Read More
Possible Link Between Depression, Limited Social Interactions During COVID-19 Pandemic
September 28th 2023Study findings showed a 10% increase in the proportion of individuals staying home due to COVID-19 policy restrictions being associated with a 0.27 increase in PHQ-9 scores for depression.
Read More
COVID-19 Pandemic Associated With Worsening Mental Health Outcomes for Adolescents
September 25th 2023To promote positive mental health outcomes, researchers urge for policy interventions that focus on home connectedness, peer friendship, and school climate while avoiding full school closures.
Read More